AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20585834
Drug: Genotype-guided dosing
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided dosing algorithm for warfarin therapy
Trial: 20585834
Drug: Mean warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean warfarin requirements ≤ 3 mg/day
Trial: 20585834
Drug: Mean warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean warfarin requirements > 3 mg/day
Trial: 17902000
Drug: Therapy group
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy group (TG) received one-session cognitive behavior therapy (CBT).
Trial: 17902000
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list group (WG) did not receive therapy during the study period.
Trial: 2595039
Drug: Alfentanil (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (median dose 1.1 mg, range 0.5-2.6 mg)
Trial: 2595039
Drug: Papaveretum (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaveretum (median dose 10 mg, range 5-15 mg) and Diazepam (median dose 8 mg, range 0-20 mg)
Trial: 1106038
Drug: Safapryn (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safapryn (3.6 g aspirin + 3.0 g paracetamol daily)
Trial: 1106038
Drug: Phenylbutazone (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone (3000 mg)
Trial: 1106038
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg phenylbutazone daily
Trial: 31625704
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (ACE inhibitors or ARBs)
Trial: 28760590
Drug: Clotrimazole vaginal
RxNorm normalized name: Clotrimazole Vaginal Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole vaginal ointment
Trial: 28760590
Drug: Honey vaginal
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey vaginal ointment
Trial: 21663857
Drug: Docetaxel 38
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 38 mg/m²
Trial: 21663857
Drug: Vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m²
Trial: 15830733
Drug: Intranasal cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine (1 mg/kg every 30 min) with oral alcohol (1 g/kg following the initial cocaine dose and a second drink at +60 min)
Trial: 12855610
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of zoledronic acid (Zol)
Trial: 12855610
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of zoledronic acid (Zol)
Trial: 9856709
Drug: Fentanyl (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (3 microg/ml) alone
Trial: 9856709
Drug: Fentanyl with
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl with 0.5 microg/ml epinephrine
Trial: 9856709
Drug: Fentanyl with
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl with both 0.01% bupivacaine and 0.5 microg/ml epinephrine
Trial: 382154
Drug: 1% domperidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% domperidone drops (0.3 mg/kg t.d.s. before meals)
Trial: 382154
Drug: 1% metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% metoclopramide drops (0.3 mg/kg t.d.s. before meals)
Trial: 11383934
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (tPA) treatment with imaging exclusion criteria
Trial: 26419527
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (tPA) treatment
Trial: 31508533
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (Mg) during even-numbered chemotherapy courses (arm AB)
Trial: 31508533
Drug: No magnesium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No magnesium supplementation during odd-numbered chemotherapy courses (arm BA)
Trial: 31508533
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (Mg)
Trial: 27443660
Drug: Pharmathen quetiapine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmathen quetiapine 400 mg prolonged-release formulation
Trial: 27443660
Drug: AstraZeneca Seroquel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AstraZeneca Seroquel Prolong® 400 mg prolonged-release formulation
Trial: 22173140
Drug: Mass distribution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass distribution of a single dose of oral azithromycin for trachoma
Trial: 21526662
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion (TCI) with propofol 4 microg/ml and remifentanil 4 ng/ml
Trial: 21526662
Drug: Manually controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually controlled infusion (MCI) with conventional-dose-weight infusion method
Trial: 21526662
Drug: Manually controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually controlled infusion (MCI)
Trial: 15836571
Drug: 3-mg subcutaneous
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-mg subcutaneous sumatriptan
Trial: 15836571
Drug: 6-mg subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mg subcutaneous sumatriptan
Trial: 11950434
Drug: Maharishi Vedic
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maharishi Vedic Medicine (MVM)
Trial: 11950434
Drug: Modern medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern medicine (conventional dietary, exercise, and multivitamin approaches)
Trial: 11950434
Drug: Maharishi Vedic
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maharishi Vedic Medicine (MVM) for high-risk subjects
Trial: 11950434
Drug: Modern medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern medicine for high-risk subjects
Trial: 11950434
Drug: Maharishi Vedic
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maharishi Vedic Medicine (MVM) overall
Trial: 8590577
Drug: Albendazole sulphoxide
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole sulphoxide (ABZS) administered orally
Trial: 29346367
Drug: Albendazole (ABZ)
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole (ABZ) administered orally
Trial: 81655
Drug: Inosiplex (drug-treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosiplex (drug-treated patients)
Trial: 31050628
Drug: Iclaprim with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iclaprim with MIC > 8 µg/ml
Trial: 23458162
Drug: Veriset™ haemostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veriset™ haemostatic patch
Trial: 23458162
Drug: Fibrin sealant
RxNorm normalized name: FIBRIN SEALANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealant patch (TachoSil(®))
Trial: 21191313
Drug: Tailored individual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tailored individual doses of radioiodine (¹³¹I) and low-dose antithyroid drug (ATD)
Trial: 21191313
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with fixed dose of radioiodine set as 2.96 MBq/g of thyroid
Trial: 21191313
Drug: Low-dose ATD
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ATD used in study group
Trial: 12682825
Drug: benfluorex (150-450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benfluorex (150-450 mg/day)
Trial: 10548199
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline 7.2%-hydroxyethyl starch 6% solution (HS-HES group)
Trial: 10548199
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline 7.2% solution (HS group)
Trial: 10548199
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch 6% solution (HES group)
Trial: 8913317
Drug: Chlorambucil (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil (before and after treatment)
Trial: 7199345
Drug: Remid preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remid preparation of allopurinol, 300 mg p.o. dose
Trial: 7199345
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation of allopurinol, 300 mg p.o. dose
Trial: 21621629
Drug: Extracorporeal photopheresis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal photopheresis (ECP) administered 3 times during week 1, then twice weekly until week 12, followed by 2 treatments monthly until week 24.
Trial: 16568198
Drug: Tropisetron-Propofol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron-Propofol (5 mg tropisetron and 0.5 mg/kg propofol)
Trial: 12937042
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (fish oil capsules rich in DHA)
Trial: 12937042
Drug: Placebo supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplementation (placebo capsules)
Trial: 21122499
Drug: Budesonide-MMX® 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide-MMX® 9 mg tablets
Trial: 10464783
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg/die)
Trial: 10464783
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine (ACh) infusion in 4 patients
Trial: 2142294
Drug: BN 52063
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BN 52063 240 mg p.o. 3 hours before exercise challenge
Trial: 2142294
Drug: BN 52063
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BN 52063 5 mg by inhalation 30 minutes before exercise challenge
Trial: 349439
Drug: Quinestrol 2
RxNorm normalized name: quinestrol
DrugBank: Quinestrol (DB04575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinestrol 2 mg single dose
Trial: 349439
Drug: Tace 72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tace 72 mg every 12 hours for 2 days
Trial: 7115012
Drug: imipramine hydrochloride,
RxNorm normalized name: Imipramine Hydrochloride, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imipramine hydrochloride, 150 mg daily
Trial: 7115012
Drug: amitriptyline hydrochloride,
RxNorm normalized name: Amitriptyline Hydrochloride, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amitriptyline hydrochloride, 150 mg daily
Trial: 30727721
Drug: Topotecan (1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.75 mg/m2 IV) and gemcitabine (starting dose 700 mg/m2 with increments of 100 mg/m2) administered on days 1, 8, and 15 every 28 days.
Trial: 30504736
Drug: Aspirin therapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin therapy (80–325 mg)
Trial: 26900146
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 mcg subcutaneously daily)
Trial: 26964731
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Teriparatide and Denosumab
Trial: 627129
Drug: Intravenous labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous labetalol (1.5 mg/kg)
Trial: 31349862
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg daily aspirin
Trial: 27023008
Drug: Twice‐daily detemir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice‐daily detemir
Trial: 22608262
Drug: Active chemotherapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active chemotherapy
Trial: 15893011
Drug: Topotecan (T)
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan (T) 1.0 mg/m2 d 1-5 and Cisplatin (DDP) 75 mg/m2 d 5 (arm A)
Trial: 15893011
Drug: Topotecan (T)
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan (T) 1.5 mg/m2 d 1-3 and Cisplatin (DDP) 75 mg/m2 d 3 (arm B)
Trial: 11826245
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (Nutropin, 1 mg/m2/day)
Trial: 7786960
Drug: L-365,260, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-365,260, 30 mg qid
Trial: 375401
Drug: Butorphanol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (2 mg)
Trial: 375401
Drug: Butorphanol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (4 mg)
Trial: 24359265
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (FPS and CO2 FS)
Trial: 24359265
Drug: Treatment within
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment within 3 years of scar development
Trial: 24359265
Drug: Treatment >3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment >3 years after scar development
Trial: 19789403
Drug: Hawthorn 450
RxNorm normalized name: Hawthorn 450 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hawthorn 450 mg twice daily
Trial: 12085156
Drug: Risedronate 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 50 mg once a week
Trial: 11453887
Drug: Perindopril (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4, 8, 16 mg) in HV; 4 mg in CHF patients
Trial: 9743163
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (BDP, TA, and placebo)
Trial: 3208513
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 10 mg x 2 for seven days
Trial: 3208513
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 25 mg x 2 for seven days
Trial: 3208513
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 50 mg x 2 for seven days
Trial: 29925684
Drug: Intranasal carbetocin
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal carbetocin
Trial: 20880120
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m² on days 1, 4, 8, and 11 of a 3-week cycle with rituximab 375 mg/m² on day 1 (21 patients)
Trial: 20880120
Drug: Bortezomib 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.6 mg/m² and rituximab on days 1, 8, 15, and 22 of a 5-week cycle (with rituximab given only in cycles 1 and 4) (21 patients)
Trial: 18397330
Drug: Metronidazole for
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole for 5 days, 20 mg/kg/day for children and 1.5 g/day for adults
Trial: 18397330
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of ornidazole, 30 mg/kg for children and 2 g for adults
Trial: 10568908
Drug: Concurrent steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent steroid use allowed in seven trials.
Trial: 10568908
Drug: Post-randomization steroid
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-randomization steroid use instructions specified in 3 of 14 trials where steroids were not part of the intervention.
Trial: 10568908
Drug: Steroid dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid dosing during the intervention reported as a secondary outcome measure in four trials.
Trial: 10568908
Drug: Free concurrent
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free concurrent steroid use during the intervention allowed in 11 RCTs.
Trial: 3023712
Drug: Oral cyclosporine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine, 14 mg/kg/d
Trial: 19583558
Drug: Hormone treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone treatment close to the menopausal transition
Trial: 16874014
Drug: COMBAT protocol
RxNorm normalized name: Provita Combat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMBAT protocol (daily celecoxib, 13-cisretinoic acid, metronomic temozolomide, low-dose etoposide)
Trial: 10840169
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of exogenous testosterone
Trial: 2166452
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (EM) with positive HSV serology
Trial: 7265455
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (drug group)
Trial: 14660506
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate diet (HCHO) at 8.5 g CHO x kg(‐1) x day(‐1)
Trial: 14660506
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (Con) at 5.4 g CHO x kg(‐1) x day(‐1)
Trial: 9407678
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus epidural morphine (3 mg every 8 hours)
Trial: 9407678
Drug: Patient-controlled epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia (PCEA) with morphine (2 mg bolus, 0.15 mg/h)
Trial: 8143997
Drug: rectal cisapride
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rectal cisapride (30 mg three times daily)
Trial: 8143997
Drug: meperidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine (1 mg/kg over 3 hours)
Trial: 30036412
Drug: Systemic steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroid treatment
Trial: 31474354
Drug: Single-agent niraparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent niraparib
Trial: 26163202
Drug: Lobeglitazone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone (0.5 mg) administered with amlodipine (10 mg)
Trial: 26163202
Drug: Amlodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (10 mg) administered with lobeglitazone (0.5 mg)
Trial: 24294746
Drug: M+M+G (Metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M+M+G (Metronidazole + Metronidazole + Lactobacillus casei var rhamnosus - Lcr 35)
Trial: 11701431
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg testosterone enanthate
Trial: 11701431
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg testosterone enanthate
Trial: 26706665
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss intervention and Metformin
Trial: 24886455
Drug: Mechanical traction
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical traction (12 treatments over six consecutive weeks)
Trial: 17508190
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg hyperbaric 0.5% levobupivacaine
Trial: 17508190
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hyperbaric 0.5% levobupivacaine
Trial: 17508190
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg hyperbaric 0.5% levobupivacaine